Rare seizure specialist Marinus Pharmaceuticals (Nasdaq: MRNS) has announced positive top-line results from the Phase III Marigold trial of oral ganaxolone.
The firm is testing the GABA receptor modulator in children and young adults with CDKL5 deficiency disorder (CDD), a rare, genetic epilepsy with refractory seizures.
Marinus stock leapt 70% in after-hours trading following the announcement. The firm said it would submit to the US regulator for approval in this indication in mid-2021, with a European submission to follow soon after.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze